Literature DB >> 21715616

Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities.

Hien T Tran1, Frank M LaFerla, David M Holtzman, David L Brody.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized pathologically by progressive neuronal loss, extracellular plaques containing the amyloid-β (Aβ) peptides, and neurofibrillary tangles composed of hyperphosphorylated tau proteins. Aβ is thought to act upstream of tau, affecting its phosphorylation and therefore aggregation state. One of the major risk factors for AD is traumatic brain injury (TBI). Acute intra-axonal Aβ and diffuse extracellular plaques occur in ∼30% of human subjects after severe TBI. Intra-axonal accumulations of tau but not tangle-like pathologies have also been found in these patients. Whether and how these acute accumulations contribute to subsequent AD development is not known, and the interaction between Aβ and tau in the setting of TBI has not been investigated. Here, we report that controlled cortical impact TBI in 3xTg-AD mice resulted in intra-axonal Aβ accumulations and increased phospho-tau immunoreactivity at 24 h and up to 7 d after TBI. Given these findings, we investigated the relationship between Aβ and tau pathologies after trauma in this model by systemic treatment of Compound E to inhibit γ-secretase activity, a proteolytic process required for Aβ production. Compound E treatment successfully blocked posttraumatic Aβ accumulation in these injured mice at both time points. However, tau pathology was not affected. Our data support a causal role for TBI in acceleration of AD-related pathologies and suggest that TBI may independently affect Aβ and tau abnormalities. Future studies will be required to assess the behavioral and long-term neurodegenerative consequences of these pathologies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715616      PMCID: PMC3146343          DOI: 10.1523/JNEUROSCI.0858-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  82 in total

1.  Diffuse axonal injury in non-missile head injury.

Authors:  J H Adams
Journal:  Injury       Date:  1982-03       Impact factor: 2.586

2.  Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.

Authors:  Salvatore Oddo; Lauren Billings; J Patrick Kesslak; David H Cribbs; Frank M LaFerla
Journal:  Neuron       Date:  2004-08-05       Impact factor: 17.173

3.  PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations.

Authors:  Lia Baki; Junichi Shioi; Paul Wen; Zhiping Shao; Alexander Schwarzman; Miguel Gama-Sosa; Rachael Neve; Nikolaos K Robakis
Journal:  EMBO J       Date:  2004-06-10       Impact factor: 11.598

4.  Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma.

Authors:  Xiao-Han Chen; Robert Siman; Akira Iwata; David F Meaney; John Q Trojanowski; Douglas H Smith
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

5.  Diffuse axonal injury and traumatic coma in the primate.

Authors:  T A Gennarelli; L E Thibault; J H Adams; D I Graham; C J Thompson; R P Marcincin
Journal:  Ann Neurol       Date:  1982-12       Impact factor: 10.422

6.  Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury.

Authors:  Milos D Ikonomovic; Kunihiro Uryu; Eric E Abrahamson; John R Ciallella; John Q Trojanowski; Virginia M-Y Lee; Robert S Clark; Donald W Marion; Stephen R Wisniewski; Steven T DeKosky
Journal:  Exp Neurol       Date:  2004-11       Impact factor: 5.330

Review 7.  Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury.

Authors:  M Arundine; M Tymianski
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

8.  Head injury in man and experimental animals: clinical aspects.

Authors:  T A Gennarelli
Journal:  Acta Neurochir Suppl (Wien)       Date:  1983

9.  Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease.

Authors:  Emmanuel Planel; Tomohiro Miyasaka; Thomas Launey; De-Hua Chui; Kentaro Tanemura; Shinji Sato; Ohoshi Murayama; Koichi Ishiguro; Yoshitaka Tatebayashi; Akihiko Takashima
Journal:  J Neurosci       Date:  2004-03-10       Impact factor: 6.167

Review 10.  Identification of the role of presenilins beyond Alzheimer's disease.

Authors:  Gopal Thinakaran; Angèle T Parent
Journal:  Pharmacol Res       Date:  2004-10       Impact factor: 7.658

View more
  99 in total

1.  Traumatic Brain Injury Alters the Metabolism and Facilitates Alzheimer's Disease in a Murine Model.

Authors:  Dandan Lou; Yao Du; Daochao Huang; Fang Cai; Yun Zhang; Tinyu Li; Weihui Zhou; Hongchang Gao; Weihong Song
Journal:  Mol Neurobiol       Date:  2017-08-03       Impact factor: 5.590

2.  Amyloid precursor protein revisited: neuron-specific expression and highly stable nature of soluble derivatives.

Authors:  Qinxi Guo; Hongmei Li; Samson S K Gaddam; Nicholas J Justice; Claudia S Robertson; Hui Zheng
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

Review 3.  Dementia resulting from traumatic brain injury: what is the pathology?

Authors:  Sharon Shively; Ann I Scher; Daniel P Perl; Ramon Diaz-Arrastia
Journal:  Arch Neurol       Date:  2012-10

Review 4.  Association of traumatic brain injury with subsequent neurological and psychiatric disease: a meta-analysis.

Authors:  David C Perry; Virginia E Sturm; Matthew J Peterson; Carl F Pieper; Thomas Bullock; Bradley F Boeve; Bruce L Miller; Kevin M Guskiewicz; Mitchel S Berger; Joel H Kramer; Kathleen A Welsh-Bohmer
Journal:  J Neurosurg       Date:  2015-08-28       Impact factor: 5.115

Review 5.  Axonal pathology in traumatic brain injury.

Authors:  Victoria E Johnson; William Stewart; Douglas H Smith
Journal:  Exp Neurol       Date:  2012-01-20       Impact factor: 5.330

6.  Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model.

Authors:  Lee E Goldstein; Andrew M Fisher; Chad A Tagge; Xiao-Lei Zhang; Libor Velisek; John A Sullivan; Chirag Upreti; Jonathan M Kracht; Maria Ericsson; Mark W Wojnarowicz; Cezar J Goletiani; Giorgi M Maglakelidze; Noel Casey; Juliet A Moncaster; Olga Minaeva; Robert D Moir; Christopher J Nowinski; Robert A Stern; Robert C Cantu; James Geiling; Jan K Blusztajn; Benjamin L Wolozin; Tsuneya Ikezu; Thor D Stein; Andrew E Budson; Neil W Kowall; David Chargin; Andre Sharon; Sudad Saman; Garth F Hall; William C Moss; Robin O Cleveland; Rudolph E Tanzi; Patric K Stanton; Ann C McKee
Journal:  Sci Transl Med       Date:  2012-05-16       Impact factor: 17.956

Review 7.  Hyperphosphorylated tau is implicated in acquired epilepsy and neuropsychiatric comorbidities.

Authors:  Ping Zheng; Sandy R Shultz; Chris M Hovens; Dennis Velakoulis; Nigel C Jones; Terence J O'Brien
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

8.  Ablation of matrix metalloproteinase-9 gene decreases cerebrovascular permeability and fibrinogen deposition post traumatic brain injury in mice.

Authors:  Nino Muradashvili; Richard L Benton; Kathryn E Saatman; Suresh C Tyagi; David Lominadze
Journal:  Metab Brain Dis       Date:  2014-04-29       Impact factor: 3.584

9.  Interferon-stimulated gene 15 as a general marker for acute and chronic neuronal injuries.

Authors:  Ren-Gang Wang; Marcus Kaul; Dong-Xian Zhang
Journal:  Sheng Li Xue Bao       Date:  2012-10-25

10.  Human apolipoprotein E4 worsens acute axonal pathology but not amyloid-β immunoreactivity after traumatic brain injury in 3xTG-AD mice.

Authors:  Rachel E Bennett; Thomas J Esparza; Hal A Lewis; Eddie Kim; Christine L Mac Donald; Patrick M Sullivan; David L Brody
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.